文献速递结核与非结核分枝杆菌细菌感染、耐药与抗菌药物

既往使用新药/伴药治疗对接受贝达喹啉和德拉马尼联合治疗的耐多药和利福平耐药结核病患者临床结局的影响

Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis.
PubMed 文献 · Clin Infect Dis · 2024-01-01

该回顾性队列研究纳入格鲁吉亚2017年11月至2020年12月接受贝达喹啉和德拉马尼联合挽救方案治疗的106例肺结核MDR/RR-TB患者。既往暴露于新药/伴药者痰培养阴转率65.9% vs 未暴露者98.0%(P < .001),治疗有利结局率41.0% vs 82.3%(P < .001)。作者认为既往暴露与新药/伴药治疗与不良临床结局及获得性耐药相关。

要点

  • 既往暴露于新药/伴药者痰培养阴转率65.9% vs 未暴露者98.0%(P < .001)。
  • 既往暴露于新药/伴药者治疗有利结局率41.0% vs 未暴露者82.3%(P < .001)。
  • 21例有基线和重复药敏试验的患者中5例(23.8%)获得贝达喹啉耐药。

核心结论

  • 既往暴露于新药/伴药结核药物与不良临床结局及获得性耐药相关。
  • 作者认为根据每例患者药敏试验结果和疾病负担调整结核方案并加强依从性支持可能改善结局。

研究设计与样本

  • 回顾性队列研究,纳入格鲁吉亚2017年11月至2020年12月在项目条件下接受贝达喹啉和德拉马尼联合作为挽救方案一部分的肺结核MDR/RR-TB患者。
  • 共106例,中位年龄39.5岁,44例(41.5%)既往接受过新药/伴药结核药物治疗。

主要发现

  • 既往暴露于新药/伴药者基线耐药率高于未暴露者:贝达喹啉15.2% vs 1.8%,利奈唑胺22.2% vs 16.7%。
  • 既往暴露与未暴露于新药/伴药者的痰培养阴转率分别为65.9% vs 98.0%(P < .001)。
  • 既往使用与未使用新药/伴药者的治疗有利结局率分别为41.0% vs 82.3%(P < .001)。
  • 32例(30.2%)患者治疗依从性≤80%。
  • 21例有基线和重复药敏试验的患者中5例(23.8%)获得贝达喹啉耐药;QTC/F间期延长(>500 ms)罕见(2.8%)。

临床怎么用

  • 作者认为根据每例患者药敏试验结果和疾病负担调整结核方案并加强依从性支持可能改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There are scarce data on the clinical outcomes of persons retreated with new/companion anti-tuberculosis (TB) drugs for multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB). We sought to evaluate the efficacy and safety of bedaquiline and delamanid containing regimens among patients with and without prior exposure to the new/companion drugs (bedaquiline, delamanid, linezolid, clofazimine, and fluoroquinolones). METHODS: We conducted a retrospective cohort study among patients with pulmonary MDR/RR-TB in Georgia who received bedaquiline and delamanid combination as a part of a salvage regimen from November 2017 to December 2020 in a programmatic setting. RESULTS: Among 106 persons with a median age of 39.5 years, 44 (41.5%) were previously treated with new/companion TB drugs. Patients with prior exposure to new/companion drugs had higher rates of baseline resistance compared to those without exposure to new/companion TB drugs (bedaquiline 15.2% vs 1.8%, linezolid 22.2% vs 16.7%). Sputum culture conversion rates among patients exposed and not exposed to new/companion drugs were 65.9% vs 98.0%, respectively (P < .001). Among patients with and without prior new/companion TB drug use, favorable outcome rates were 41.0% and 82.3%, respectively (P < .001). Treatment adherence in 32 (30.2%) patients was ≤80%. Five of 21 patients (23.8%) who had a baseline and repeat susceptibility test had acquired bedaquiline resistance. QTC/F prolongation (>500 ms) was rare (2.8%). CONCLUSIONS: Prior exposure to new/companion TB drugs was associated with poor clinical outcomes and acquired drug resistance. Tailoring the TB regimen to each patient's drug susceptibility test results and burden of disease and enhancing adherence support may improve outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Mikiashvili L, Kempker RR, Chakhaia TS, et al. Impact of Prior Tuberculosis Treatment With New/Companion Drugs on Clinical Outcomes in Patients Receiving Concomitant Bedaquiline and Delamanid for Multidrug- and Rifampicin-Resistant Tuberculosis. Clin Infect Dis. 2024. PMID: 37962987. doi:10.1093/cid/ciad694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。